Literature DB >> 20355027

Identifications of inhibitors of IgE production by human lymphocytes isolated from 'Cha Chuukanbohon Nou 6' tea leaves.

Daiki Honma1, Motoyuki Tagashira, Tomomasa Kanda, Mari Maeda-Yamamoto.   

Abstract

BACKGROUND: Tea (Camellia sinensis L.) is consumed all over the world and in especially large quantities in Japan and China, where it has been used not only as a daily beverage but also for medicinal purposes for thousands of years. Tea has been found to exhibit various bioregulatory activities, including antiallergic, anticarcinogenic, antimetastatic, antioxidative, antihypertensive, antihypercholesterolemic, anti-dental caries and antibacterial effects, and to influence intestinal flora.
RESULTS: Cha Chuukanbohon Nou 6 is a tea cultivar improved by the National Institute of Vegetable and Tea Science (NIVTS) in Japan. On comparing chemical constituents of 11 varieties of tea leaves by high-performance liquid chromatography, we found two new major compounds in Cha Chuukanbohon Nou 6. Nuclear magnetic resonance spectroscopy revealed these compounds to be theogallin and 1,2-di-O-galloyl-4,6-O-(S)-hexahydroxydiphenoyl-beta-D-glucopyranose. The two were similar in chemical structure to strictinin, an inhibitor of immunoglobulin (Ig) production. Thus their effects on the production of Igs by peripheral blood lymphocytes were tested. Both compounds, like strictinin, inhibited IgE production.
CONCLUSION: The results suggest Cha Chuukanbohon Nou 6 to be the basis of an antiallergic beverage. Copyright (c) 2009 Society of Chemical Industry.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20355027     DOI: 10.1002/jsfa.3807

Source DB:  PubMed          Journal:  J Sci Food Agric        ISSN: 0022-5142            Impact factor:   3.638


  1 in total

1.  Metabolomics-driven nutraceutical evaluation of diverse green tea cultivars.

Authors:  Yoshinori Fujimura; Kana Kurihara; Megumi Ida; Reia Kosaka; Daisuke Miura; Hiroyuki Wariishi; Mari Maeda-Yamamoto; Atsushi Nesumi; Takeshi Saito; Tomomasa Kanda; Koji Yamada; Hirofumi Tachibana
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.